- Home
- IBIO vs LPCN Comparison
IBIO vs LPCN Comparison
Compare IBIO & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- LPCN
- Stock Information
- Founded
- IBIO 2008
- LPCN 1997
- Country
- IBIO United States
- LPCN United States
- Employees
- IBIO N/A
- LPCN N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- LPCN Health Care
- Exchange
- IBIO Nasdaq
- LPCN Nasdaq
- Market Cap
- IBIO 16.4M
- LPCN 18.2M
- IPO Year
- IBIO N/A
- LPCN N/A
- Fundamental
- Price
- IBIO $1.48
- LPCN $2.62
- Analyst Decision
- IBIO Strong Buy
- LPCN Strong Buy
- Analyst Count
- IBIO 4
- LPCN 1
- Target Price
- IBIO $4.50
- LPCN $8.00
- AVG Volume (30 Days)
- IBIO 8.3M
- LPCN 34.7K
- Earning Date
- IBIO 10-31-2025
- LPCN 11-07-2025
- Dividend Yield
- IBIO N/A
- LPCN N/A
- EPS Growth
- IBIO N/A
- LPCN N/A
- EPS
- IBIO N/A
- LPCN N/A
- Revenue
- IBIO $400,000.00
- LPCN $4,208,119.00
- Revenue This Year
- IBIO N/A
- LPCN N/A
- Revenue Next Year
- IBIO $33.34
- LPCN N/A
- P/E Ratio
- IBIO N/A
- LPCN N/A
- Revenue Growth
- IBIO 77.78
- LPCN N/A
- 52 Week Low
- IBIO $0.56
- LPCN $2.53
- 52 Week High
- IBIO $6.89
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- IBIO 61.97
- LPCN 35.81
- Support Level
- IBIO $1.02
- LPCN $2.52
- Resistance Level
- IBIO $1.81
- LPCN $2.92
- Average True Range (ATR)
- IBIO 0.26
- LPCN 0.13
- MACD
- IBIO 0.03
- LPCN -0.04
- Stochastic Oscillator
- IBIO 63.87
- LPCN 9.68
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.